Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 14/20 | 0.69 |
| ▸ | FAAH | O00519 | 3/20 | 0.69 |
| ▸ | GPX4 | P36969 | 1/20 | 0.61 |
| ▸ | CDK4 | P11802 | 3/20 | 0.57 |
| ▸ | CCND1 | P24385 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL8718251 | 0.96 | TRPV1 (0.68) | TRPV1FAAHGPX4CDK4CCND1 | |
| Propionic Acid SCHEMBL8716868 | 0.93 | TRPV1 (0.64) | TRPV1FAAHGPX4CDK4CCND1 | |
| SCHEMBL6474214 | 0.91 | LMNA (0.60) | TRPV1FAAHGPX4CDK4CCND1 | |
| SCHEMBL29357331 | 0.90 | MAPT (0.69) | TRPV1FAAHLMNAMAPTBAZ2B | |
| SCHEMBL2241936 | 0.90 | MAPT (0.69) | TRPV1FAAHLMNAMAPTBAZ2B | |
| SCHEMBL21154454 | 0.89 | LMNA (0.55) | TRPV1FAAHGPX4CDK4CCND1 | |
| Acetic Acid SCHEMBL8714196 | 0.87 | MAPT (0.68) | TRPV1FAAHLMNAMAPTBAZ2B | |
| SCHEMBL2270578 | 0.87 | PARP1 (0.57) | TRPV1FAAHGPX4CDK4CCND1 | |
| SCHEMBL9439297 | 0.86 | UCHL1 (0.61) | TRPV1FAAHGPX4CDK4CCND1 | |
| SCHEMBL9439306 | 0.86 | UCHL1 (0.61) | TRPV1FAAHGPX4CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112010914-B | Glucosamine modified pentacyclic piperazine dione and preparation and application thereof | 首都医科大学 | 2023-06-27 | — | — | CN | claimed |
| CN-115720578-B | And tricyclic derivatives, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-110621675-B | Tricyclic compounds useful for the treatment of proliferative diseases | 阿古诺治疗有限公司 | 2023-09-19 | — | — | CN | disclosed |
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | AC IMMUNE SA (CH) | 2023-08-17 | — | — | US | disclosed |
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | AC IMMUNE SA (CH) | 2023-08-17 | — | — | US | disclosed |
| US-11684625-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates | AC IMMUNE SA (CH) | 2023-06-27 | — | — | US | disclosed |
| US-11684625-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates | AC IMMUNE SA (CH) | 2023-06-27 | — | — | US | disclosed |
| CN-115720578-A | Tricyclic derivative, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-02-28 | — | — | CN | disclosed |
| EP-3596073-B1 | TRICYCLIC COMPOUNDS FOR USE IN TREATMENT OF PROLIFERATIVE DISORDERS. | ARGONAUT THERAPEUTICS LTD (GB) | 2022-05-11 | — | — | EP | disclosed |
| US-20200325132-A1 | TRICYCLIC COMPOUNDS FOR USE IN TREATMENT OF PROLIFERATIVE DISORDERS | Argonaut Therapeutics Limited (GB) | 2020-10-15 | — | — | US | disclosed |
| US-6498251-B1 | Tetrahydrobenzindole derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-12-24 | — | — | US | disclosed |
| US-6469020-B2 | AS INHIBITORS OF MATRIX METALLOPROTEINASE, FOR THERAPY OF DISEASES SUCH AS DEGENERATIVE DISEASES AND CERTAIN CANCERS | DARWIN DISCOVERY, LTD. (GB) | 2002-10-22 | — | — | US | disclosed |
| US-20020013333-A1 | Hydroxamic and carboxylic acid derivatives | DARWIN DISCOVERY LIMITED (GB) | 2002-01-31 | — | — | US | disclosed |
| EP-1057814-A1 | TETRAHYDROBENZINDOLE DERIVATIVES | Meiji Seika Kaisha, Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
| EP-0716661-B1 | PSEUDO- AND NON-PEPTIDE BRADYKININ RECEPTOR ANTAGONISTS | SCIOS INC (US) | 2000-04-05 | — | — | EP | disclosed |
| US-5817756-A | USING A MODIFIED DI- OR TRI-PEPTIDES | SCIOS INC. (US) | 1998-10-06 | — | — | US | disclosed |
| US-5563147-A | CENTRAL NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0716661-A1 | PSEUDO- AND NON-PEPTIDE BRADYKININ RECEPTOR ANTAGONISTS | SCIOS NOVA INC. (US) | 1996-06-19 | — | — | EP | disclosed |
| EP-0705832-A1 | Serotonergic modulators | LILLY INDUSTRIES LIMITED (GB) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995007294-A1 | PSEUDO- AND NON-PEPTIDE BRADYKININ RECEPTOR ANTAGONISTS | SCIOS NOVA INC. (US) | 1995-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | MAPT, MAP1LC3A, MAP1LC3B | TRPV1 3673/4885FAAH 2411/4885GPX4 3126/4885 |
| US-20020013333-A1 | Hydroxamic and carboxylic acid derivatives | HCAR2, HCAR1, CBR1 | TRPV1 3956/4885FAAH 443/4885GPX4 3705/4885 |
| US-11684625-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates | MAPT, PSEN2, PSEN1 | TRPV1 4131/4885FAAH 2860/4885GPX4 2272/4885 |
| US-20200325132-A1 | TRICYCLIC COMPOUNDS FOR USE IN TREATMENT OF PROLIFERATIVE DISORDERS | PRMT5, HDAC5, CDK15 | TRPV1 3352/4885FAAH 4207/4885GPX4 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.